Diagnósticos da América (DASA3) Q2 2026 earnings summary

Executive summary

• Achieved strong progress in strategy focused on simplification, profitable growth, and financial strengthening, with revenue growth, efficiency gains, increased cash generation, and deleveraging in 2Q26.

• Consolidated EBITDA reached R$446 million in 2Q26, up 53% year-over-year, with margin expansion of 5.8 p.p.; free cash flow totaled R$292 million, and net debt reduced by R$23 million.

• Completed R$700 million debenture issuance to refinance short-term obligations and extend debt maturity, enhancing financial flexibility.

• Focused on innovation, technology, and digitalization to enhance patient care, operational efficiency, and recognized for innovation in medical services.

• Maintained financial discipline with active liability management and improved liquidity.

Financial highlights

• Consolidated gross revenue reached R$2.4 billion in 2Q26, up 9.2% in Diagnostics and down 4% in Hospitals and Oncology Northeast compared to 2Q25 Current Scope.

• Consolidated EBITDA was R$446 million (+53%), with margin expanding to 20.1% (+5.8 p.p.); net loss reduced to R$35 million from R$454 million year-over-year.

• Free cash flow improved to R$292 million in 2Q26, reversing a negative result from the prior year.

• Net financial debt at R$5.6 billion after acquisitions payable and receivables anticipation, with leverage at 3.52x Net Debt/EBITDA.

• Cash conversion cycle reduced by 7 days compared to 2Q25.

Outlook and guidance

• Confident in continued growth across all segments, with July showing acceleration and positive trends.

• Continued focus on disciplined execution, cash generation, efficient capital allocation, and value creation.

• Second half of the year anticipated to be more favorable for cash generation due to seasonality.